
PepGen Inc’s (NASDAQ:PEPG) lead asset, PGN-EDO51 for Duchenne muscular dystrophy (DMD), is in phase 1 clinical trials in healthy volunteers with data expected by the end of the year, according to BofA Securities.
The PepGen Analyst: Tazeen Ahmad initiated coverage of PepGen with a Buy rating and a price objective at $16.